glp 1 agonist with dpp 4 inhibitor GLP-1 Receptor Agonists Have better Outcomes Than DPP4 Inhibitors in T2D patients & CKD GLP 1 Receptor Agonists and

J Neurochem (2005) 92:798806

GLP-1 receptor agonists are medications for type 2 diabetes and obesity that mimic the incretin hormone GLP-1

Another pathway through which macrophage cell formation was suppressed was via cAMP activation

The FDA released a safety announcement in 2015 which alerted providers to report severe and persistent joint pain with use of DPP-4 inhibitors

We dont have much data yet and the Phase I so far was mixed, with Phase II data coming this year

The most common reasons include: Gastrointestinal side effects such as nausea, vomiting and diarrhea which are the single most frequently documented reason for stopping in large health system datasets High out of pocket cost and lack of insurance coverage particularly in individuals without diabetes Medication unavailability or pharmacy supply shortages which peaked in 2023early 2024 Perceived completion of therapy once target weight is reached or weight loss plateaus Concerns about long term safety or treatment burden of injections Many cohorts show substantial discontinuation by 3 months, with further losses by 6-9 months